LRPAP1 and cancer: Furthermore, the effect of CEP65 on matrix metalloproteinase (MMP)2 activity and the expression levels of the metastasis-associated genes, RAP, vitronectin (VTN) and tissue inhibitor of metalloproteinases-2 (TIMP-2), were investigated to establish whether CEP65 is an oncogene and a potential target for cancer therapy.